Images List Premium Download Classic

Pharmaceutically Acceptable Salt

Pharmaceutically Acceptable Salt-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Peptide macrocycles against acinetobacter baumannii
August 17, 2017 - N°20170233437

Wherein x1 to x8 and r1 to r8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (i), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by acinetobacter baumannii.
Compositions and methods for treating cns disorders
Sage Therapeutics, Inc.
August 17, 2017 - N°20170233433

Described herein are neuroactive steroids of the formula (i): or a pharmaceutically acceptable salt thereof; wherein, r1, r2a, r2b, r3 and a are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as gaba modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, ...
Novel compounds
Sage Therapeutics, Inc.
August 17, 2017 - N°20170233430

And pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of sting (stimulator of interferon genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous ...
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tricyclic p13k inhibitor compounds and methods of use
Msd R&d (china) Co., Ltd.
August 17, 2017 - N°20170233407

Formula i compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
Yangtze River Pharmaceutical Group Co., Ltd.
August 17, 2017 - N°20170233395

The present invention relates to a 2,4-disubstituted 7h-pyrrolo[4,3-d]pyrimidin derivative, a preparation method and a medicinal use thereof. In particular, the present invention discloses a compound of formula (i) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. For the definition of each group in formula (i), see the description tbr ...
Novel compounds as ror gamma modulators
Glenmark Pharmaceuticals S.a.
August 17, 2017 - N°20170233380

The present disclosure is directed to compounds of formula (i) and pharmaceutically acceptable salts thereof, wherein ring a, ring b, l, r1, r2, r3, r4, r5, ra, rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (rorγt). These compounds prevent, inhibit, or suppress the action ...
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Aryl and heteroaryl fused lactams
Shanghai Shaletech Technology Co., Ltd.
August 17, 2017 - N°20170233368

In which r1, r2, u, v, l, m, r5, m, x, y and z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
Neuroactive substituted cyclopent[a]anthracenes as modulators for gaba type-a receptors
Washington University
August 17, 2017 - N°20170233356

The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to gaba function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
Prmt1 inhibitors and uses thereof
Epizyme, Inc.
August 17, 2017 - N°20170233347

Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting prmt1 activity. Methods of using the compounds for treating prmt1-mediated disorders are also described.
Process for the synthesis of (+) and (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
Euthymics Bioscience, Inc.
August 17, 2017 - N°20170233333

The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e. G., depression, anxiety disorders, eating disorders and urinary ...
Methods for treatment of and prophylaxis against inflammatory disorders
The University Of Utah Research Foundation
August 17, 2017 - N°20170232081

An isolated and purified peptide, neonatal net-inhibitory factor (nnif), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering net-inhibitory peptides (nips), which may be a nnif, a pharmaceutically acceptable salt of a nnif, a nnif analog, a pharmaceutically acceptable salt of a nnif ...
Aza-heteroaryl compounds as pi3k-gamma inhibitors
The University Of Utah Research Foundation
August 17, 2017 - N°20170232016

And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
Sage Therapeutics, Inc.
August 17, 2017 - N°20170232006

The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to gaba function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
Pharmaceutically Acceptable Salt Patent Pack
Download 1713+ patent application PDFs
Pharmaceutically Acceptable Salt Patent Applications
Download 1713+ Pharmaceutically Acceptable Salt-related PDFs
For professional research & prior art discovery
inventor
  • 1713+ full patent PDF documents of Pharmaceutically Acceptable Salt-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compounds for use in treating acute coronary syndrome and related conditions
Vitae Pharmaceuticals, Inc.
August 17, 2017 - N°20170231992

Provided herein are compounds and pharmaceutically acceptable salts thereof that are useful therapeutics for acute coronary syndrome and related disorders.
Multi-layered tablet containing drug unstable to light
Shionogi & Co., Ltd.
August 17, 2017 - N°20170231989

An oral disintegrating tablet which contains rosuvastatin or a salt thereof and is stable to light is provided. An oral disintegrating tablet stable to light, temperature and humidity can be provided by preparing a multi-layered tablet containing rosuvastatin or a pharmaceutically acceptable salt thereof as an active ingredient, a light stabilizer, and an inorganic salt or a basic oxide.
Compounds for inflammation and immune-related uses
Synta Pharmaceuticals Corp.
August 17, 2017 - N°20170231984

The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
Astellas Ireland Co., Ltd.
August 17, 2017 - N°20170231974

The combined use of (r)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3r)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (luts/bph) ...
Treatment of ocular inflammatory diseases using laquinimod
Teva Pharmaceutical Industries, Ltd.
August 17, 2017 - N°20170231971

Disclosed is a method for treating an ocular inflammatory disease (oid), e. G., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an oid, uveitis, bacterial conjunctivitis, viral ...
Pharmaceutical compositions of edoxaban
Sandoz Ag
August 17, 2017 - N°20170231969

Edoxaban is factor x inhibitor useful for the treatment or the prevention of thrombosis or embolism. A pharmaceutical composition comprising edoxaban, or a pharmaceutically acceptable salt thereof, a water soluble vinylpyrrolidone polymer selected from the group consisting of povidone and copovidone, and a cellulose ether, and not comprising a sugar alcohol, having good dissolution and bioavailability is provided. A process ...
Inhibition of il-2 production
Sandoz Ag
August 17, 2017 - N°20170231966

Wherein r1 to r4 and a are as defined in the present specification, or a pharmaceutically acceptable salt thereof.
Pharmaceutical composition for modified release
Astellas Pharma Inc.
August 17, 2017 - N°20170231965

A pharmaceutical composition for modified release, comprising (1) (r)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive ...
Loading